4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta‐analysis and Cost‐Effectiveness Study That Focuses on Compliance and Liver Toxicity | Zendy

Panayiotis D. Ziakas | Zendy; Eleftherios Mylonakis | Zendy

Open Access

4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta‐analysis and Cost‐Effectiveness Study That Focuses on Compliance and Liver Toxicity

Author(s) -

Panayiotis D. Ziakas,

Eleftherios Mylonakis

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/647944

Subject(s) - medicine , isoniazid , discontinuation , confidence interval , tuberculosis , regimen , relative risk , latent tuberculosis , rifampicin , chemoprophylaxis , population , surgery , mycobacterium tuberculosis , pathology , environmental health

One-third of the world's population is infected with tuberculosis, and 9 months of isoniazid monotherapy is the treatment of choice for latent tuberculosis infection. However, this approach has been associated with hepatotoxicity and poor compliance. A shorter (4-month) rifampin regimen has been evaluated in recent clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research